Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, November 2000, p. 2985-2990, Vol. 44, No. 11
Clinical Mycology Section, Laboratory of
Clinical Investigation, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Bethesda, Maryland
20892,1 and 2nd Department of Internal
Medicine, Nagasaki University, School of Medicine, 1-7-1 Sakamoto,
Nagasaki 852-8061, Japan2
Received 4 April 2000/Returned for modification 31 May
2000/Accepted 1 August 2000
High-level azole resistance in the Darlington strain of
Candida albicans was investigated by gene replacement in
C. albicans and expression in Saccharomyces
cerevisiae. We sequenced the ERG11 gene, which
encodes the sterol C14
0066-4804/00/$04.00+0
Genetic Analysis of Azole Resistance in the
Darlington Strain of Candida albicans
-demethylase, from our copy of the
Darlington strain. Both alleles contained the histidine for tyrosine
substitution at position 132 (Y132H) reported in Darlington by others,
but we also found a threonine-for-isoleucine substitution (I471T) not
previously reported in the C. albicans ERG11. The encoded
I471T change in amino acids conferred azole resistance when
overexpressed alone and increased azole resistance when added to the
Y132H amino acid sequence in an S. cerevisiae expression
system. Replacement of one copy of ERG11 in an
azole-susceptible strain of C. albicans with a single copy
of the Darlington ERG11 resulted in expression of the
integrated copy and a modest increase in azole resistance. The profound
azole resistance of the Darlington strain is the result of multiple mutations.
*
Corresponding author. Mailing address: Clinical Center,
Rm. 11C304, NIH, Bethesda, MD 20892. Phone: (301) 496-3461. Fax: (301) 480-0050. E-mail: jb46y{at}nih.gov.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»